Precision for Medicine Acquires ACT Oncology         


President and CEO

Pat Devitt Risse, Pharm.D. founded ACT Oncology in 2000 as a niche, oncology consultancy. Since the company’s inception, Dr. Devitt Risse has guided the company’s growth into the robust, global organization that it is today - providing expert clinical development services on behalf of  a diverse client base of leading biotech, pharmaceutical and non-profit oncology organizations.  As President of ACT Oncology, she provides executive leadership to the company and strategic protocol design and study optimization guidance on behalf of the company’s Sponsors. 

Dr. Devitt Risse and ACT Oncology have extensive experience in conducting Phase I-IV trials involving most indications for both solid tumor, as well as hematologic malignancies. Since 2009, Dr. Devitt Risse has worked closely with the Multiple Myeloma Research Foundation consortium of physicians to create a landmark and synergistic “collaborative” research approach to help find a cure for multiple myeloma. 

Dr. Devitt Risse earned her Doctor of Pharmacy from Rutgers University and was named by NJBIZ as one of the Best 50 Women in Business in 2014 and as a EY Finalist for Entrepreneur Of The Year© award for the state of New Jersey in 2015. Dr. Devitt Risse has more than two decades of broad-based oncology experience in both global and domestic clinical research environments, including large pharmaceutical companies, biotech companies and CROs.    

Patrica DevittLowRes_0350_061

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at to see how we’re delivering the next generation of CRO services for oncology innovators.